A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects With Melanoma Who Previously Received Talimogene Laherparepvec
Phase of Trial: Phase IV
Latest Information Update: 19 May 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 14 Mar 2016 Planned End Date changed from 1 Apr 2023 to 1 Mar 2023, according to ClinicalTrials.gov record.
- 14 Mar 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2023, according to ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.